Laronidase - Biologic Drug Details

Summary for laronidase

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for laronidase

Recent Clinical Trials for laronidase

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Cinnagen	PHASE3
Masonic Cancer Center, University of Minnesota
The Ryan Foundation	N/A

See all laronidase clinical trials

Pharmacology for laronidase

Established Pharmacologic Class	Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
Chemical Structure	alpha-Glucosidases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for laronidase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for laronidase Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2019-04-29	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2017-04-14	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2018-12-15	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2020-03-27	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2020-02-25	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2018-04-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for laronidase Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2036-12-20	Patent claims search
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2036-08-10	Patent claims search
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2036-06-14	Patent claims search
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2034-03-11	Patent claims search
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2038-12-19	Patent claims search
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058		2034-05-02	Patent claims search

International Patents for laronidase

Country	Patent Number	Estimated Expiration
Japan	2007010428
European Patent Office	2002021
Japan	2004069309
Japan	4470999
Austria	E524194
Japan	WO2006038695

Market Dynamics and Financial Trajectory for Laronidase

Last updated: February 13, 2026

Laronidase, marketed as Aldurazyme by BioMarin, is approved for mucopolysaccharidosis I (MPS I), a rare genetic disorder characterized by enzyme deficiency leading to glycosaminoglycan accumulation. The drug was approved by the FDA in 2003 and has maintained a dominant position in its niche.

Market Size and Growth Drivers

The global MPS I prevalence is approximately 1 in 100,000 live births, with higher incidences in certain populations. The prevalence of diagnosed cases, however, remains lower due to diagnostic challenges.

Market valuation:

• As of 2022, the global biologic drug market for rare diseases was valued at approximately $200 billion, with enzyme replacement therapies (ERTs) accounting for an estimated 15% ($30 billion).
• Laronidase's specific market is smaller due to rare disease prevalence, with estimates ranging from $150 million to $250 million annually.

Growth drivers:

• Increasing diagnosis rates driven by improved screening.
• Expansion of geographic markets, notably in Asia and Latin America.
• Potential label expansions for other indications or earlier treatment stages.

Constraints:

• Limited patient pool due to disease rarity.
• High treatment costs, which can affect market penetration.
• Competitive landscape, though options are limited given the rare disease specificity.

Competition and Pipeline

Laronidase remains the sole approved enzyme for MPS I, giving it a monopoly. However, small pipeline products aim to address limitations such as immune responses or delivery issues:

• Gene therapy approaches from companies like Ultragenyx and Pfizer are in early-phase trials.
• Substrate reduction therapies are under development but have yet to reach clinical efficacy.

Financial Trajectory

Revenue trends:

• BioMarin reported Aldurazyme revenues of approximately $160 million in 2022.
• Revenue growth has hovered around 3-5% annually, influenced by new patient initiation rates and geographic expansion.

Pricing:

• The wholesale acquisition cost (WAC) in the U.S. is roughly $380,000 per year per patient.
• International pricing varies, often lower due to healthcare system differences.

Cost considerations:

• High manufacturing costs due to complex bioprocessing.
• Significant R&D expenses for pipeline development and regulatory compliance.

Profitability:

• BioMarin reports gross margins around 70% for Aldurazyme.
• Net margins are affected by R&D, marketing, and distribution expenses, typically ranging from 20-30%.

Future Outlook

Market growth will depend on:

• Population growth and improved diagnosis.
• Potential approval of new formulations or dosing regimens.
• Price negotiations with healthcare payers.
• The emergence of gene therapy, which could disrupt the ERT market.

Analysis from Evaluate Pharma predicts a compound annual growth rate (CAGR) of approximately 4% for the enzyme replacement therapy segment for rare diseases through 2027.

Regulatory and Policy Impact

Orphan drug designations provide benefits like tax credits and market exclusivity, which are critical for the financial sustainability of products like laronidase.

In 2020, the FDA offered priority review vouchers which can be sold or transferred, creating an additional revenue stream for developers.

Summary

Laronidase maintains a stable market position strongly driven by the limited patient population, high product prices, and regulatory exclusivity. Future growth hinges on expanding diagnosed cases, geographic reach, and pipeline innovations. Competition remains limited but evolving biotech pipelines pose potential future threats or opportunities.

---

Key Takeaways

• The global market for laronidase is approximately $150-$250 million annually.
• Revenue growth is moderate, around 3-5% annually.
• Price points are high, roughly $380,000 per patient annually in the U.S.
• BioMarin's gross margins are approximately 70%, with net margins of 20-30%.
• Market expansion and pipeline developments will influence future trajectory.

---

FAQs

1. What factors most influence laronidase's market growth?
Diagnosis rates, geographic expansion, pricing negotiations, and pipeline pipeline advancements.

2. How does laronidase compare to other enzyme replacement therapies?
Laronidase is unique to MPS I; few competitors exist due to disease rarity. Its high price is comparable to other ERTs but varies by indication.

3. What regulatory incentives support laronidase?
Orphan drug designation, market exclusivity, priority review vouchers.

4. How might gene therapy impact laronidase's market?
Gene therapies promise potential for one-time treatments, potentially reducing the ERT market share if proven safe and effective.

5. What are the main challenges facing laronidase commercially?
Limited patient pool, high costs, and emerging gene therapies.

---

References

[1] Evaluate Pharma. Market forecast reports, 2022-2027. [2] BioMarin Annual Reports, 2022. [3] U.S. FDA. Approved drug labels and policy updates.